Lilly preps FDA run for ‘triple-G’ weight loss drug with Phase 3 data
NDA FilingretatrutidePositive
AI Analysis
Summary
Eli Lilly plans to file for FDA approval of retatrutide in Q1 2027 based on Phase 3 TRIUMPH-2 and TRIUMPH-3 trial data showing over 20% weight loss at 80 weeks. Earlier Phase 3 TRIUMPH-1 data demonstrated 28.3% weight loss.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Phase 3 TRIUMPH-2 and TRIUMPH-3 trials showed weight loss of over 20% at 80 weeks; TRIUMPH-1 showed 28.3% weight loss
Importance:8/10
Sentiment:
0.85
Weight LossPhase 3NDA FilingRetatrutideGLP-1 Agonist
Related Companies
Read the original article
Published by BioSpace on July 23, 2026 12:53 PM